Escolar Documentos
Profissional Documentos
Cultura Documentos
This seminar covers the most recent information on denition, epidemiology, and clinical causes of acute renal
failure. The mechanisms of acute prerenal failure and the potential interference by commonly used drugs of
autoregulation of renal blood ow are discussed. We summarise some basic and recent insights into the
haemodynamic and cellular pathophysiological mechanisms, mainly of postischaemic acute renal failure. Recent
ndings on the repair mechanisms of renal injury and the potential future therapeutic possibilities are discussed.
We provide some differential diagnostic approaches for patients with acute renal failure and summarise prevention
of the disorder and management of critically ill patients by dialysis and by other means. Finally, some information
on the inuence of gene polymorphisms on the prognosis of acute renal failure is given.
Acute renal failure is the generic term for an abrupt and
sustained decrease in renal function resulting in
retention of nitrogenous (urea and creatinine) and nonnitrogenous waste products. Depending on the severity
and duration of the renal dysfunction, this accumulation
is accompanied by metabolic disturbances, such as
metabolic acidosis and hyperkalaemia, changes in body
uid balance, and effects on many other organ systems.
Denitions of acute renal failure range from severe (ie,
that requiring dialysis) to slight increases in serum
creatinine concentration (eg, of 442 mol/L). In the
absence of a universal denition, a reasonable denition
of acute renal failure is an acute and sustained increase
in serum creatinine concentration of 442 mol/L if the
baseline is less than 221 mol/L, or an increase in
serum creatinine concentration of more than 20% if the
baseline is more than 221 mol/L.1
The Acute Dialysis Quality Initiative group lately
proposed the RIFLE system (table 1), classifying acute
renal failure into three severity categories (risk, injury,
and failure) and two clinical outcome categories (loss
and end-stage renal disease).24
Epidemiology
Causes of acute renal failure can be broadly divided into
three categories (gure 1). In the prerenal form there is
a reversible increase in serum creatinine and blood urea
concentrations; it results from decreased renal
perfusion, which leads to a reduction in glomerular
ltration rate (GFR). Postrenal acute renal failure is due
to obstruction of the urinary collection system by either
intrinsic or extrinsic masses. The remaining patients
have the renal form, in which structures of the nephron,
such as the glomeruli, tubules, vessels, or interstitium,
are affected.
The major cause of intrinsic renal azotaemia is acute
tubular necrosis. This disorder is caused by ischaemic or
nephrotoxic injury to the kidney and is a specic
histopathological and pathophysiological entitiy, which
can result from several distinct renal insults. Prerenal
azotaemia and ischaemic acute tubular necrosis occur
on a continuum of the same pathophysiological process
and together account for 75% of the cases of acute renal
failure.5 Although the terms acute renal failure and acute
www.thelancet.com Vol 365 January 29, 2005
Risk
Injury
Failure
Loss
End-stage
renal disease
GFR criteria
417
Seminar
Prerenal
Intrinsic renal
Vascular
Vasculitis,
malignant
hypertension
Acute
glomerulonephritis
Postinfectious
glomerulonephritis,
disease caused by
antibody to glomerular
basement membrane
Postrenal
Acute
interstitial
nephritis
Drugassociated
Acute
tubular
necrosis
Obstruction of
collecting system
or extrarenal drainage
Bladder-outlet obstruction
Bilateral ureteral obstruction
Ischaemic
Exogenous
Antibiotics
(gentamicin)
Radio contrast agents
Cisplatin
Nephrotoxic
Endogenous
Intratubular pigments (haemoglobinuria,
myoglobinuria)
Intratubular proteins (myeloma)
Intratubular crystals (uric acid, oxalate)
Seminar
Seminar
Microvascular
Tubular
Decreased
oxygen
Glomerular
Medullary
Increased vasoconstriction
in response to:
endothelin, adenosine,
angiotensin II,
thromboxane A2,
leukotrienes,
sympathetic nerve
activity
Cytoskeletal breakdown
Loss of cell polarity
Inflammatory
and vasoactive
mediators
Decreased vasodilation in
response to:
nitric oxide,
prostaglandin E2,
acetylcholine, bradykinin
Histology
The typical histological features of human acute tubular
necrosis include vacuolation, loss of brush border in
proximal tubular cells, and sloughing of tubular cells
into the lumen, leading to cast obstruction. Interstitial
oedema with mild to moderate leucocyte inltration can
produce widely spaced tubules. Although the disorder is
named necrosis, frankly necrotic cells are not a common
nding and histological evidence of injury is limited in
many cases despite striking functional impairment.62,63
With advanced injury, tubular epithelial cells detach
from the basement membrane and contribute to
www.thelancet.com Vol 365 January 29, 2005
Seminar
Tubular factors
Renal ischaemia results in rapid loss of cytoskeletal
integrity and cell polarity with shedding of the proximal
tubule brush border, mislocalisation of adhesion
molecules and other membrane proteins such as the
www.thelancet.com Vol 365 January 29, 2005
Loss of polarity
Apical
surface
Loss of
brush border
Ischaemia and
reperfusion
Basolateral
surface
Apoptotic
epithelial
cell
Viable
epithelial
cell
Integrin
Tubular
lumen
Na+/K+
ATPase
Epithelial cell
with brush border
Necrosis and
cell death
Luminal
obstruction
Seminar
Diagnostic approach
The diagnostic approach to acute renal failure includes
a careful history and record review, a thorough physical
examination, and the judicious interpretation of
laboratory data, including examination of the urinary
sediment and other urinary chemistry, and appropriate
ultrasonographic and radiological investigations.100,101
Serum creatinine
In acute renal failure, renal function is commonly
monitored by following the daily variations in serum
creatinine concentration. However, this variable has
limitations as a marker of GFR in patients with acute
renal failure. The serum creatinine concentration
depends not only on urinary clearance of creatinine but
also on the rate of production and the volume of
distribution.
Furthermore,
serum
creatinine
concentration does not accurately reect GFR in the nonsteady-state condition of acute renal failure. Correct
interpretation of serum creatinine concentrations is
hampered by the variation in calibration of the different
creatinine assays.102104
www.thelancet.com Vol 365 January 29, 2005
Seminar
Serum cystatin C
Among newer markers, serum cystatin C has not yet
been well validated as a GFR indicator in acute renal
failure.105,106 However, some studies have found it to be
an early and reliable marker of acute renal failure in
patients in intensive-care units.107109
Urine volume
Acute anuria or severe oliguria are quite specic
indicators of acute renal failure, although severe acute
renal failure can exist despite normal urine output.
Changes in urine output can occur long before
biochemical changes are apparent. Prerenal forms of
acute renal failure nearly always present with oliguria
(400 mL/day), although non-oliguric forms have been
reported.110 Postrenal and renal forms of acute renal
failure can present with any pattern of urine ow
ranging from anuria to polyuria.
Urinalysis
Specic gravity
Osmolality (mmol/kg)
Sodium (mmol/L)
Fractional excretion of sodium (%)
Fractional excretion of urea (%)
Fractional excretion of uric acid (%)
Fractional excretion of lithium (%)
Low-molecular-weight proteins
Brush-border enzymes
Prerenal
Renal
Hyaline casts
1020
500
20
1
35
7
7
Low
Low
Abnormal
1010
300
40
2
35
15
20
High
High
100
Biomarkers
Several biomarkers have been proposed for the early
diagnosis of acute renal failure and are currently under
study.112,113 These include urinary interleukin 18114 and
tubular enzymes, such as the intestinal form of alkaline
phosphatase, N-acetyl--glucosaminidase, and alanine
aminopeptidase.115 Kidney injury molecule 1, a type-1
transmembrane protein, is extensively expressed in
proximal tubule cells in biopsy samples from patients with
conrmed acute tubular necrosis, and the normalised
concentrations of this protein were signicantly higher in
ischaemic acute tubular necrosis than in other forms of
acute renal failure or chronic renal disease.116
Identication of urinary proteins expressed during
acute renal failure might lead to the identication of
www.thelancet.com Vol 365 January 29, 2005
Volume expansion
The preventive and therapeutic value of volume
expansion alone is not easy to estimate, because uids
are commonly included as part of the overall
management of patients in clinical studies, together
with the administration of diuretics, dopamine, or both.
The value of volume therapy and the nature of uids
423
Seminar
N-acetylcysteine
Three meta-analyses during the past 2 years140142 have
concluded that, compared with periprocedural hydration
alone, oral acetylcysteine with hydration signicantly
lowers the risk of contrast nephropathy in patients with
chronic renal insufciency. We should emphasise that
acetylcysteine without adequate hydration is not
sufcient and that in some of these studies the
individual contribution of acetylcysteine is difcult to
delineate. However, every meta-analysis also found
studies showing no benet. Furthermore, acetylcysteine
seems to affect the tubular handling of creatinine
directly, so a decrease in serum creatinine concentration
with this drug does not necessarily lead to a protective
effect on the GFR.143
Calcium-channel blockers
Some investigators have shown that the prophylactic
administration of calcium-channel blockers protects
424
Seminar
Advantages
Disadvantages
Table 3: Advantages and disadvantages of intermittent versus continuous renal replacement therapy
425
Seminar
Prognosis
When acute renal failure is severe enough to necessitate
renal replacement therapy, in-hospital mortality is high,
exceeding 50%.9,12,174 Mortality is extremely high in
critically ill patients who have multiorgan failure.10,175,176
Mortality rates have changed little over the past few
decades despite signicant advances in supportive care;
however, this lack of improvement may be more
apparent than real because patients nowadays are older
and have more pre-existing chronic health problems.177
Certain combinations of gene polymorphism are related
to the risk of death among patients with acute renal
failure who need dialysis.178,179 The combination of a high
concentration of tumour necrosis factor and a
genotype leading to low production of interleukin 10 was
associated with a higher risk of death than for patients
with low concentrations of tumour necrosis factor and
genotypes conferring intermediate or high production of
interleukin 10.
426
Seminar
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
427
Seminar
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
428
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
Al Awqati Q, Oliver JA. Stem cells in the kidney. Kidney Int 2002;
61: 38795.
Hammerman MR, Miller SB. Therapeutic use of growth factors in
renal failure. J Am Soc Nephrol 1994; 5: 111.
Rookmaaker MB, Verhaar MC, Van Zonneveld AJ, Rabelink TJ.
Progenitor cells in the kidney: biology and therapeutic perspectives.
Kidney Int 2004; 66: 51822.
Krause DS, Theise ND, Collector MI, et al. Multi-organ, multilineage engraftment by a single bone marrow-derived stem cell.
Cell 2001; 105: 36977.
Verfaillie CM, Pera MF, Lansdorp PM. Stem cells: hype and reality.
Hematology (American Society of Hematology Education Program)
2002: 36991.
Ito T. Stem cells of the adult kidney: where are you from?
Nephrol Dial Transplant 2003; 18: 64144.
Poulsom R, Forbes SJ, Hodivala-Dilke K, et al. Bone marrow
contributes to renal parenchymal turnover and regeneration.
J Pathol 2001; 195: 22935.
Kale S, Karihaloo A, Clark PR, Kashgarian M, Krause DS,
Cantley LG. Bone marrow stem cells contribute to repair of the
ischemically injured renal tubule. J Clin Invest 2003; 112: 4249.
Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are
renotropic, helping to repair the kidney and improve function in
acute renal failure. J Am Soc Nephrol 2004; 15: 1794804.
Togel F, Isaac J, Westenfelder C. Hematopoietic stem cell
mobilization-associated granulocytosis severely worsens acute
renal failure. J Am Soc Nephrol 2004; 15: 126167.
Anderson RJ, Barry DW. Clinical and laboratory diagnosis of
acute renal failure. Best Pract Res Clin Anaesthesiol 2004; 18: 120.
Kieran N, Brady HR. Clinical evaluation, management, and
outcome of acute renal failure. In: Johnson RJ, Feehally J, eds.
Comprehensive clinical nephrology, 2nd edn. Edinburgh: Mosby,
2003: 183206.
Wuyts B, Bernard D, Van Den Noortgate N, et al. Reevaluation of
formulas for predicting creatinine clearance in adults and
children, using compensated creatinine methods. Clin Chem
2003; 49: 101114.
Delanghe JR. Standardization of creatinine determination and its
consequences for the clinician. Acta Clin Belg 2002; 57: 17275.
Coresh J, Astor BC, McQuillan G, et al. Calibration and random
variation of the serum creatinine assay as critical elements
of using equations to estimate glomerular ltration rate.
Am J Kidney Dis 2002; 39: 92029.
Schuck O, Teplan V, Jabor A, Stollova M, Skibova J. Glomerular
ltration rate estimation in patients with advanced chronic renal
insufciency based on serum cystatin C levels. Nephron Clin Pract
2003; 93: c14651.
Schuck O, Teplan V, Sibova J, Stollova M. Predicting the
glomerular ltration rate from serum creatinine, serum cystatin
C and the Cockcroft and Gault formula with regard to drug
dosage adjustment. Int J Clin Pharmacol Ther 2004; 42: 9397.
Delanaye P, Lambermont B, Chapelle JP, Gielen J, Gerard P,
Rorive G. Plasmatic cystatin C for the estimation of glomerular
ltration rate in intensive care units. Intensive Care Med 2004; 30:
98083.
Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection
of acute renal failure by serum cystatin C. Kidney Int 2004; 66:
111522.
Rickli H, Benou K, Ammann P, et al. Time course of serial
cystatin C levels in comparison with serum creatinine after
application of radiocontrast media. Clin Nephrol 2004; 61:
98102.
Miller PD, Krebs RA, Neal BJ, McIntyre DO. Polyuric prerenal
failure. Arch Intern Med 1980; 140: 90709.
Carvounis CP, Nisar S, Guro-Razuman S. Signicance of the
fractional excretion of urea in the differential diagnosis of acute
renal failure. Kidney Int 2002; 62: 222329.
Finn WF, Porter GA. Urinary biomarkers and nephrotoxicity. In:
De Broe ME, Porter GA, Bennet WM, Verpooten GA, eds.
Clinical nephrotoxins renal injury from drugs and chemicals,
2nd edn. Dordrecht: Kluwer Academic Publishers, 2003: 62255.
Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for
renal diseases. J Am Soc Nephrol 2004; 15: 167789.
Seminar
114 Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary
interleukin-18 is a marker of human acute tubular necrosis.
Am J Kidney Dis 2004; 43: 40514.
115 Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D,
Morgan TJ. Measurement of tubular enzymuria facilitates early
detection of acute renal impairment in the intensive care unit.
Nephrol Dial Transplant 2003; 18: 54351.
116 Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV.
Kidney injury molecule-1 (KIM-1): a novel biomarker for human
renal proximal tubule injury. Kidney Int 2002; 62: 23744.
117 Hampel DJ, Sansome C, Sha M, Brodsky S, Lawson WE,
Goligorsky MS. Toward proteomics in uroscopy: urinary protein
proles after radiocontrast medium administration.
J Am Soc Nephrol 2001; 12: 102635.
118 Conger JD. Interventions in clinical acute renal failure: what are the
data? Am J Kidney Dis 1995; 26: 56576.
119 Dishart MK, Kellum JA. An evaluation of pharmacological
strategies for the prevention and treatment of acute renal failure.
Drugs 2000; 59: 7991.
120 Kellum JA. What can be done about acute renal failure?
Minerva Anestesiol 2004; 70: 18188.
121 Lameire NH, De Vriese AS, Vanholder R. Prevention and
nondialytic treatment of acute renal failure. Curr Opin Crit Care
2003; 9: 48190.
122 Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of
hyperuricemia and tumor lysis syndrome in lymphoid
malignancies. Clin Lymphoma 2003; 3: 22532.
123 De Vriese AS, Bourgeois M. Pharmacologic treatment of acute
renal failure in sepsis. Curr Opin Crit Care 2003; 9: 47480.
124 De Vriese AS. Prevention and treatment of acute renal failure in
sepsis. J Am Soc Nephrol 2003; 14: 792805.
125 Choi PT, Yip G, Quinonez LG, Cook DJ. Crystalloids vs colloids in
uid resuscitation: a systematic review. Crit Care Med 1999; 27:
20010.
126 Ragaller MJ, Theilen H, Koch T. Volume replacement in critically
ill patients with acute renal failure. J Am Soc Nephrol 2001;
12 (suppl 17): S3339.
127 Waikar SS, Chertow GM. Crystalloids versus colloids for
resuscitation in shock. Curr Opin Nephrol Hypertens 2000; 9:
50104.
128 Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R.
A comparison of albumin and saline for uid resuscitation in the
intensive care unit. N Engl J Med 2004; 350: 224756.
129 Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast
media-associated nephropathy: randomized comparison of
2 hydration regimens in 1620 patients undergoing coronary
angioplasty. Arch Intern Med 2002; 162: 32936.
130 Kellum JA. Use of diuretics in the acute care setting.
Kidney Int Suppl 1998; 66: S6770.
131 Schetz M. Should we use diuretics in acute renal failure?
Best Pract Res Clin Anaesthesiol 2004; 18: 7589.
132 Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the
management of acute renal failure: a prospective, double-blind,
placebo-controlled, randomized study. Nephrol Dial Transplant
1997; 12: 259296.
133 Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics,
mortality, and nonrecovery of renal function in acute renal failure.
JAMA 2002; 288: 254753.
134 Mehta RL, Chertow GM. Diuretics in critically ill patients with
acute renal failure. JAMA 2003; 289: 137981.
135 Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in
acute renal failure. Crit Care Med 2004; 32: 166977.
136 Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Lowdose dopamine in patients with early renal dysfunction: a placebocontrolled randomised trial. Lancet 2000; 356: 213943.
137 Denton MD, Chertow GM, Brady HR. Renal-dose dopamine for
the treatment of acute renal failure: scientic rationale,
experimental studies and clinical trials. Kidney Int 1996; 50: 414.
138 Kellum JA, Decker M. Use of dopamine in acute renal failure: a
meta-analysis. Crit Care Med 2001; 29: 152631.
139 Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml J, Hiesmayr
M. Lack of renoprotective effects of dopamine and furosemide
during cardiac surgery. J Am Soc Nephrol 2000; 11: 97104.
429
Seminar
430